Valeria Ventura is the Senior Director of Business Development at BioAgilytix, leading efforts across the UK, Ireland, and Southern Europe. With a PhD in Biochemistry from Imperial College London, specializing in structural glycomics and proteomics, Valeria combines scientific expertise with over a decade of commercial experience in the CRO industry. Having started her career at the lab bench before moving into business development, she has supported preclinical and clinical drug development from discovery to market and partners with pharmaceutical and biotech sponsors to navigate complex bioanalytical challenges and drive successful development programs.

Robert Nelson, PhD, provides scientific and regulatory consultation, focusing on our EU team and customers, to help guide bioanalysis supporting drug development. Spending over fifteen years working in regulated (GLP/GCP) laboratory environments, Dr. Nelson supports preclinical and clinical drug development programs, with broad experience in bioanalysis, immunogenicity, and biomarkers. He joined BioAgilytix from Labcorp Drug Development’s Scientific Affairs team, where he partnered with clients, operations, and other scientists to address science, technology, and regulatory challenges. Prior to this, he led the bioanalytical laboratory team at Swiss biotech company Novimmune. Dr. Nelson holds his PhD in Molecular Physiology and B.Sc. with Honours in Pharmacology from the University of Edinburgh. 

Gareth Satchell is an Associate Director at GSK, specializing in the support and oversight of outsourced PK, ADA, and soluble biomarker clinical assays across multiple therapeutic areas. After graduating from the University of Sheffield with a bachelor's degree in microbiology, he subsequently worked for 10 years within global clinical research organizations before joining the Bioanalytical External Study Monitor group at GSK. His work involves close collaboration both cross-functionally within GSK with clinical operations.

Matthias gained his bachelor's and master's degree in molecular biotechnology at Heidelberg University. He then took a research scientist role in Recombinant R&D Analytics at Octapharma Biopharmaceuticals, Heidelberg, developing immuno assays for product characterization and pre-clinical/clinical studies. Matthias joined the Hamburg laboratories of BioAgilytix in 2021 where he currently serves biotech and pharma sponsors as a Principal Investigator leading immunogenicity, PK and biomarker bioanalytical projects for numerous different biotherapeutic modalities.